Q-omics provides the consensus-scored ANKRD13B profile across patient tissues and cancer cell-line models. ANKRD13B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ANKRD13B is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ANKRD13B RNA expression shows 23,298 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where ANKRD13B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD13B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD13B survival associations across molecular data types. ANKRD13B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD13B RNA expression–survival associations across cancer types. High ANKRD13B expression shows unfavorable associations in ACC, KIRC, LIHC, BLCA, DLBC and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ANKRD13B RNA expression.
This table summarizes ANKRD13B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD13B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD13B shows higher tumor expression in COAD, KIRP, KIRC, HNSC, LIHC and LUAD. The COAD box plot shows higher ANKRD13B RNA expression in tumor versus normal tissue (log2 FC = +2.780, t-test p < 0.001).
This table shows molecular features associated with ANKRD13B in patient tissues and cancer cell lines. In patient samples, ANKRD13B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD13B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
